Page 131 - Binder2

Durability is not an afterthought.
It is the difference between a drug that works for six
months and one that transforms the long-term course of a
disease.

If we keep defining success by short-term response, we will
continue to launch expensive biologics that are built to fail.
But if we redefine success as immune persistence, we can
finally start designing biologics that last—not just on the
market, but in the body.

This shift requires trials to run longer, and to design
endpoints that reflect staying power, not just first-past-the-
post improvement. That’s not something investors want to
hear. Time is money. However, in this instance time is
lucrative investment.

It pays in time saved from developing another drug when
the initial one rushed through trials eventually fails. It pays
in longer periods of adherence when a drug is prescribed
and continues to work. It pays in trust and confidence from
clinicians and patients alike.

Biologics that work for 90 days are not equivalent to
biologics that work for 5 years. But under the current
system, they’re approved the same way.

That’s not precision medicine. That’s expiration-dated
medicine.

129